Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- HRP Rabbit monoclonal [Y69] to c-Myc
- Suitable for: WB
- Reacts with: Human
- Conjugation: HRP
Product nameHRP Anti-c-Myc antibody [Y69]
See all c-Myc primary antibodies
DescriptionHRP Rabbit monoclonal [Y69] to c-Myc
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse, Rat
Synthetic peptide within Human c-Myc aa 1-100 (N terminal). The exact sequence is proprietary.
(Peptide available as
- WB: A20 whole cell lysate (ab7180), Raji and K562 whole cell lysates.
If you need other conjugated anti-c-myc (Y69) RabMAb antibodies, find our range of products here.
We also offer a PBS only version of this clone as product ab168727.
For more information on choosing the right c-Myc antibody for you, please visit Antibodies to c-Myc and Myc tag.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. Store In the Dark.
Storage bufferpH: 7.40
Preservative: 0.1% 10% Proclin 300 Solution
Constituents: 30% Glycerol, 1% BSA, PBS
Concentration information loading...
PurityProtein A purified
- Epigenetics and Nuclear Signaling
- Domain Families
- HLH / Leucine Zipper
- HLH / Leucine Zipper
- Anti-c-Myc antibody [Y69] - BSA and Azide free (ab168727)
- Alexa Fluor® 488 Anti-c-Myc antibody [Y69] (ab190026)
- Alexa Fluor® 647 Anti-c-Myc antibody [Y69] (ab190560)
- Alexa Fluor® 594 Anti-c-Myc antibody [Y69] (ab201775)
- Alexa Fluor® 555 Anti-c-Myc antibody [Y69] (ab201780)
- Alexa Fluor® 568 Anti-c-Myc antibody [Y69] (ab201781)
- FITC Anti-c-Myc antibody [Y69] (ab223913)
- Anti-c-Myc antibody [Y69] (ab32072)
Immunizing Peptide (Blocking)
Our Abpromise guarantee covers the use of ab205818 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/5000. Detects a band of approximately 58 kDa (predicted molecular weight: 48 kDa).Can be blocked with Human c-Myc peptide (ab166837).|
FunctionParticipates in the regulation of gene transcription. Binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Seems to activate the transcription of growth-related genes.
Involvement in diseaseNote=Overexpression of MYC is implicated in the etiology of a variety of hematopoietic tumors.
Note=A chromosomal aberration involving MYC may be a cause of a form of B-cell chronic lymphocytic leukemia. Translocation t(8;12)(q24;q22) with BTG1.
Defects in MYC are a cause of Burkitt lymphoma (BL) [MIM:113970]. A form of undifferentiated malignant lymphoma commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. Note=Chromosomal aberrations involving MYC are usually found in Burkitt lymphoma. Translocations t(8;14), t(8;22) or t(2;8) which juxtapose MYC to one of the heavy or light chain immunoglobulin gene loci.
Sequence similaritiesContains 1 basic helix-loop-helix (bHLH) domain.
modificationsPhosphorylated by PRKDC. Phosphorylation at Thr-58 and Ser-62 by GSK3 is required for ubiquitination and degradation by the proteasome.
Ubiquitinated by the SCF(FBXW7) complex when phosphorylated at Thr-58 and Ser-62, leading to its degradation by the proteasome. In the nucleoplasm, ubiquitination is counteracted by USP28, which interacts with isoform 1 of FBXW7 (FBW7alpha), leading to its deubiquitination and preventing degradation. In the nucleolus, however, ubiquitination is not counteracted by USP28, due to the lack of interaction between isoform 4 of FBXW7 (FBW7gamma) and USP28, explaining the selective MYC degradation in the nucleolus. Also polyubiquitinated by the DCX(TRUSS) complex.
Cellular localizationNucleus > nucleoplasm. Nucleus > nucleolus.
- Information by UniProt
Formc-Myc is also expressed in the cytoplasm.
- AU016757 antibody
- Avian myelocytomatosis viral oncogene homolog antibody
- bHLHe39 antibody
All lanes : HRP Anti-c-Myc antibody [Y69] (ab205818) at 1/5000 dilution
Lane 1 : Raji (Human Burkitt's lymphoma cell line) Whole Cell Lysate
Lane 2 : K562 (Human erythromyeloblastoid leukemia cell line) Whole Cell Lysate
Lysates/proteins at 10 µg per lane.
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 48 kDa
Observed band size: 58 kDa why is the actual band size different from the predicted?
Exposure time: 4 minutes
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab205818 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.
ab205818 has not yet been referenced specifically in any publications.